GoodRx (GDRX) – Research Analysts’ Recent Ratings Updates

GoodRx (NASDAQ: GDRX) recently received a number of ratings updates from brokerages and research firms:

• 11/15/2025 – GoodRx was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/11/2025 – GoodRx had its price target lowered by analysts at JPMorgan Chase & Co. from $6.00 to $5.00. They now have an “overweight” rating on the stock.
• 11/10/2025 – GoodRx had its price target lowered by analysts at TD Cowen from $7.00 to $6.00. They now have a “buy” rating on the stock.
• 11/6/2025 – GoodRx had its price target lowered by analysts at UBS Group AG from $4.25 to $4.00. They now have a “neutral” rating on the stock.
• 11/6/2025 – GoodRx had its price target lowered by analysts at Mizuho from $5.00 to $4.00. They now have a “neutral” rating on the stock.
• 10/25/2025 – GoodRx was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 10/8/2025 – GoodRx had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total transaction of $95,084.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 4.53% of the company’s stock.

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.